Long-term clinical outcomes with the next-generation Resolute Stent System: A report of the two-year follow-up from the RESOLUTE clinical trial

EuroIntervention

Volumn 5, Issue 6, 2010, Pages 692-697

  Meredith, Ian T ^a   Worthley, Stephen G ^b   Whitbourn, Robert ^c   Walters, Darren ^d   McClean, Dougal ^e   Ormiston, John ^f   Horrigan, Mark ^g   Wilkins, Gerard T ^h   Hendriks, Randall ⁱ   Matsis, Philip ^j   Muller, David ^k   Cutlip, Donald E ^l  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d THE PRINCE CHARLES HOSPITAL   (Australia)

^e CHRISTCHURCH HOSPITAL   (New Zealand)

^f Mercy Hospital   (New Zealand)

^g AUSTIN HEALTH   (Australia)

^h DUNEDIN HOSPITAL   (New Zealand)

ⁱ FREMANTLE HOSPITAL   (Australia)

^j WELLINGTON HOSPITAL   (New Zealand)

^k ST VINCENT S HOSPITAL   (Australia)

^l HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

more..

Author keywords

Coronary artery disease; Drug eluting stents; Outcomes; Zotarolimus

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; ZOTAROLIMUS; BIOMATERIAL;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; CORONARY STENT; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; IN-STENT RESTENOSIS; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; RISK FACTOR; STENT THROMBOSIS; ANGIOCARDIOGRAPHY; AUSTRALIA; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; DRUG ELUTING STENT; FOLLOW UP; GRAFT OCCLUSION; HEART MUSCLE REVASCULARIZATION; INCIDENCE; INSTRUMENTATION; MIDDLE AGED; NEW ZEALAND; PROSPECTIVE STUDY; PROSTHESIS; RADIOGRAPHY; STENT; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

AUSTRALIA; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; NEW ZEALAND; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; STENTS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77954415001     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV5I6A114     Document Type: Article

References (27)

1. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME; TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788-94.
2. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38-42.
3. Holmes DR, Jr., Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004;109:634-40.
4. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R; RAVEL Study Group. Randomized study with the sirolimuscoated BX Velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-80.
5. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJ; C-SIRIUS Investigators. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43:1110-5.
6. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G; E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362:1093-9.
7. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942-7.
8. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, Staberock M, de Feyter P, Müller R, Regar E, Degertekin M, Ligthart JM, Disco C, Backx B, Russell ME. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation. 2003;107:559-64.
9. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE; ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006;114:798-806.
10. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-23.
11. Kastrati A, Mehilli J, Pache J Kaiser C, Valgimigli M, Kelbæk H, Menichelli M, Sabaté M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schömig A Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:1030-9.
12. Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Seyfarth M, Varenne O, Dirksen MT, Percoco G, Varricchio A, Pittl U, Syvänne M, Suttorp MJ, Violini R, Schömig A. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J. 2007;28:2706-13.
13. Stone GW, Moses J, Ellis SG, Schofer J, Dawkins KD, Morice M, Colombo A, Schampaert E, Grube E, Kirtane A, Cutlip D, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998-1008.
14. Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, Jorgensen E,Marco J, Nordrehaug J-E, Ruzyllo W, Urban P, Stone GW, Wijns W. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005;26:804-847.
15. Smith SC, Jr., Feldman TE, Hirshfeld JW, Jr., Jacobs AK, Kern MJ, King SB 3rd, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006;47:e1-121.
16. Maisel WH. Unanswered questions - drug-eluting stents and the risk of late thrombosis. N Engl J Med. 2007;356:981-4.
17. Farb A, Boam AB. Stent thrombosis redux - the FDA perspective. N Engl J Med. 2007;356:984-7.
18. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C; BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584-91.
19. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005;45:2088-92.
20. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667-78.
21. Lagerqvist B, James S, Stenestrand U. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009-19.
22. Udipi K, Chen M, Cheng P, Jiang K, Judd D, Caceres A, Melder RJ, Wilcox JN. Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent. J Biomed Mater Res A. 2008;85:1064-71.
23. Meredith IT, Worthley S, Whitbourn R, Walters DL, McClean D, Horrigan M, Popma JJ, Cutlip DE, DePaoli A, Negoita M, Fitzgerald PJ, for the RESOLUTE Investigators. Clinical and angiographic results with the next-generation Resolute stent system. A prospective, multicenter, first-in-human trial. J Am Coll Cardiol Intv. 2009;2:977-85.
24. Sketch MH Jr, Ball M, Rutherford B, Popma JJ, Russell C, Kereiakes DJ; Driver investigators. Evaluation of the Medtronic (Driver) cobalt-chromium alloy coronary stent system. Am J Cardiol. 2005;95:8-12.
25. Udipi K, Melder R, Chen M, Cheng P, Hezi-Yamit A, Sullivan C; Wong J, Wilcox J. The next generation Endeavor Resolute Stent: role of the BioLinx™ polymer system. EuroIntervention. 2007;3:137-9.
26. Udipi K, Hezi-Yamit A, Chen M, Wong J, Sullivan C, Wilcox JN. Development of a novel biocompatible polymer system for extended drug release in a second generation drug eluting stent. E-poster presented at the Transcatheter Cardiovascular Therapeutics Symposium, Washington DC, October 22-27, 2006.
27. Leon MB, Kandzari D, Eisenstein E, Mauri L, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, McLaurin BT, Solomon SL, Douglas Jr JS, Popma JJ, for the ENDEAVOR IV Investigators Late safety, efficacy, and cost effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: Two-year follow-up from the ENDEAVOR IV trial. Under review at JACC Interventions 2009.